{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005406","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.252283+00:00","generated_at":"2026-05-17T12:44:07.567301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cassava Sciences Q2 2025 net loss $44.2M, including $31.25M litigation reserve; shifts focus to TSC epilepsy","bullets":["Net loss $44.2M ($0.92 per share) vs net income $6.2M in Q2 2024.","Recorded $31.25M estimated loss contingency for securities litigation settlement.","Alzheimer's program phased out; new focus on simufilam for TSC-related epilepsy - PoC study expected H1 2026.","Cash $112.4M at June 30, 2025; H2 2025 net cash use $47-51M including litigation reserve.","Appointed Dr. Hulihan (CMO), Dr. Bordey (SVP Neuroscience), Dr. Moore (SVP Clin Dev)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005406","json":"https://secwatch.observer/filing/0001171843-25-005406.json","markdown":"https://secwatch.observer/filing/0001171843-25-005406.md","text":"https://secwatch.observer/filing/0001171843-25-005406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/0001171843-25-005406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/f8k_081425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:44:07.567301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}